Kimball Electronics Trades Calm as Holiday Lulls Market Action

Kimball Electronics Trades Calm as Holiday Lulls Market Action

May 25, 2026

New York, May 25, 2026, 12:01 (EDT)

  • U.S. stock markets are shut for Memorial Day, with normal trading set to pick back up Tuesday.
  • KE ended Friday at $24.60, up 1.6%. Shares gained about 0.3% for the week.
  • The next thing to watch is if medical sales growth and cash flow can make up for weaker demand from last year.

Kimball Electronics Inc. stock finished Friday up at $24.60, recovering from a sharp 6.1% drop seen Tuesday. The rebound was weak, with shares ending just 0.3% higher than the previous week’s close. KE, which trades on Nasdaq, last changed hands on Friday as U.S. markets will not open Monday for Memorial Day. Investing

This is relevant now since the week is shortened by the holiday, not just a normal intraday trade. Nasdaq confirms markets are closed for Memorial Day, May 25. The NYSE sticks to its standard 9:30 a.m. to 4:00 p.m. Eastern session when markets are open. Nasdaq

KE shares haven’t yet made up for their early May drop. The stock is still trading about 9.5% under its May 5 close of $27.15. That was the day Kimball Electronics put out its fiscal Q3 2026 results after the bell. Shares fell 7.3% in the next full session. Investing

Kimball put out an update last week, noting CFO Jana Croom and IR head Andrew Regrut will meet investors one-on-one at the B. Riley Securities investor conference in Marina del Rey, California, May 20-21. The company did not mention any new deals or contracts in the statement. Business Wire

Kimball put up a mixed set of numbers. The company posted fiscal Q3 revenue of $352.9 million, 3.4% higher than last quarter, but below the $374.6 million recorded a year ago. Medical sales climbed 10.2% from the previous quarter. Adjusted operating margin, which cuts out certain items, landed at 4.2%. Business Wire

Kimball CEO Richard D. Phillips said the quarter was “in line with expectations” and is looking for Q4 to be a “good finish.” Phillips called medical contract manufacturing a “key part” of the company’s strategy, pointing to its work in outsourced medical production and processes. Business Wire

Investors have reason to stay wary after the latest filing. Third-quarter sales dropped year over year across all three segments. Automotive fell 3%, medical slid 8%, and industrial was down 8%. Medical sales did show some strength on a longer view, up 5% for the first nine months of the fiscal year. SEC

Cash stayed strong for Kimball. The company pulled in $14.9 million from operations this quarter. Cash conversion days fell to 90 from 99 a year ago, meaning cash moved through the business faster. At March 31, Kimball reported $82.5 million in cash on hand and $276.0 million of unused borrowing available. Business Wire

But the rebound isn’t clear-cut. Kimball’s 10-Q showed open orders fell 6% from a year ago and noted risks tied to the global economy, tariffs, supply and material costs, foreign exchange and execution on new business. Customer concentration is also a worry: Nexteer Automotive, ZF and Philips all made up more than 10% of sales last quarter. SEC

Peer tape finished stronger Friday. Sanmina jumped 5.2%, while Jabil put on 2.2% and Flex gained 1.1%. Larger electronics manufacturing services stocks outperformed. EMS refers to companies that take on design, assembly, or production of electronic products under contract.

KE faces a test this week as markets return from the break. The main thing traders are sorting out: can last week’s rebound stick, given stronger cash flow but a weak order log at this small-cap manufacturer. Management continues to push the medical side. No big moves for the ticker Monday. The debate continues.

Stock Market Today

  • 3 Reasons to Buy Cochlear Shares in June Amidst Recent Recovery
    June 15, 2026, 4:10 PM EDT. Cochlear Ltd (ASX: COH) shares have rebounded 8.5% over the past month following a steep 40.7% drop on April 22 after a shock downgrade of FY2026 profit guidance due to falling implant demand and Middle East disruptions. Despite a 60% year-to-date decline, the stock trades at $104.45, with the market likely pricing in the worst. Cochlear remains a global market leader with a 50% share in cochlear implants and a vast long-term growth potential as penetration sits at just 3% of six million addressable patients in developed markets. Broker Jarden and Wilsons Advisory foresee over 60% upside, and management emphasizes the temporary nature of recent volume weakness, backed by growing clinical need and links between implants and reduced dementia risk.